The whole-genome landscape of medulloblastoma subtypes
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and ‘enhancer hijacking’ events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma. Genomic analysis of 491 medulloblastoma samples, including methylation profiling of 1,256 cases, effectively assigns candidate drivers to most tumours across all molecular subgroups. Medulloblastomas are highly malignant brain tumours that develop during childhood. Paul Northcott and colleagues analysed the whole-genome sequences of 491 medulloblastomas in order to characterize the genomic landscape across tumours and identify new drivers and mutational signatures. Their integrative genomic analyses, including methylation profiling of 1,256 medulloblastomas, identifies subgroup-specific driver mutations and suggests additional tumour subtypes. The authors assign driver mutations to a high proportion of the less well characterized Group 3 and Group 4, which together contribute to more than 60% of all medulloblastomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The overlap observed between the G3 and G4 tumors with respect to MYC amplification supports the working hypothesis that these medulloblastomas are not easily separable in part because they originate from a shared cerebellar progenitor cell pool, with each group arising from arrest at different points along a developmental stage continuum (8, 23).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Methylation array–based classification studies have categorized the G3/G4-2, G3/G4-3, and G3/G4-4 molecular subgroups as G3; the G3/G4-1, G3/G4-5, and G3/G4-6 subgroups as a mix of G3 and G4; and the G3/G4-7 and G3/G4-8 subgroups as primarily G4 (8).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 2×
“T 0) 42 .”
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657 · cited 1×
“The relatively recent recognition of consensus MB subgroups has rapidly changed the way MB is studied in the research setting and how it is diagnosed and treated in the clinic 39 .”
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621 · cited 1×
“The functional effect of the mutations was annotated using Annovar 43 and the variants were assessed for their confidence and split into somatic and non-somatic calls.”
Principal components analysis corrects for stratification in genome-wide association studies
Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., & Reich, D. (2006) · Nature Genetics · doi:10.1038/ng1847 · Cited by 10,248
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“…previously detected in MB 16 and has been linked with underlying BRCA1 and BRCA2 mutations in breast, aggressive prostate, and pancreatic cancers 16,17 , was unexpectedly observed in most of the patients with Group 3 and Group 4 MB, and a subset of patients with SHH MB. Additional…”
Self-citationComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Topological domains in mammalian genomes identified by analysis of chromatin interactions
Dixon, J. R., Selvaraj, S., Yue, F., Kim, A., Li, Y., Shen, Y., Hu, M., Liu, J. S., & Ren, B. (2012) · Nature · doi:10.1038/nature11082 · Cited by 6,829
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information
Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G., Schmidt, T., Kiefer, F., Cassarino, T. G., Bertoni, M., Bordoli, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku340 · Cited by 4,632 · cited 1×
“Although no structure has been determined for the Kelch domain of KBTBD4 (KBTBD4 Kelch ), there is an abundance of structural data about the family that allows for construction of homology models, generated with SWISS-MODEL 64 .”
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Aryee, M. J., Jaffe, A. E., Corrada-Bravo, H., Ladd-Acosta, C., Feinberg, A. P., Hansen, K. D., & Irizarry, R. A. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu049 · Cited by 4,397
Howie, B. N., Donnelly, P., & Marchini, J. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000529 · Cited by 3,928 · cited 1×
“To improve sensitivity with regards to imbalanced and balanced regions, SNP positions in the control were phased with impute2 48 .”
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Self-citationHMDB 3.0—The Human Metabolome Database in 2013
Wishart, D. S., Jewison, T., Guo, A. C., Wilson, M., Knox, C., Liu, Y., Djoumbou, Y., Mandal, R., Aziat, F., Dong, E., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1065 · Cited by 2,845
Self-citationIntegration of biological networks and gene expression data using Cytoscape
Cline, M. S., Smoot, M., Cerami, E., Kuchinsky, A., Landys, N., Workman, C., Christmas, R., Avila-Campilo, I., Creech, M., Gross, B., et al. (2007) · Nature Protocols · doi:10.1038/nprot.2007.324 · Cited by 2,507
DELLY: structural variant discovery by integrated paired-end and split-read analysis
Rausch, T., Zichner, T., Schlattl, A., Stütz, A. M., Benes, V., & Korbel, J. O. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts378 · Cited by 2,459
Self-citationIdentification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337 · cited 1×
“IDH1 mutations represent a hallmark genetic event in adult patients with glioma that exhibit a distinct hypermethylation phenotype (that is, glioma CpG island methylator phenotype, G-CIMP) 27,28 .”
Ceccarelli, M., Barthel, F. P., Malta, T. M., Sabedot, T. S., Salama, S. R., Murray, B. A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S. M., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.028 · Cited by 2,189
Self-citationMolecular subgroups of medulloblastoma: the current consensus
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y.-J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0922-z · Cited by 1,936 · cited 1×
“epigenetic signatures that define clinically relevant patient subsets 12,13 .”
Self-citationMedulloblastoma Comprises Four Distinct Molecular Variants
Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S., Bouffet, E., Clifford, S. C., Hawkins, C. E., French, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4324 · Cited by 1,339 · cited 1×
“Notable similarities between Group 3 and Group 4 have been discussed, including ambiguous cases that exhibit features characteristic of either subgroup 33–35 .”
Self-citationDeciphering Signatures of Mutational Processes Operative in Human Cancer
Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J., & Stratton, M. R. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.12.008 · Cited by 1,277
WGS500 Consortium, Rimmer, A., Phan, H., Mathieson, I., Iqbal, Z., Twigg, S. R. F., Wilkie, A. O. M., McVean, G., & Lunter, G. (2014) · Nature Genetics · doi:10.1038/ng.3036 · Cited by 1,057 · cited 1×
“Raw calls for indels were obtained from Platypus (v.0.7.4) 44 .”
InfluentialA community-driven global reconstruction of human metabolism
Thiele, I., Swainston, N., Fleming, R. M. T., Hoppe, A., Sahoo, S., Aurich, M. K., Haraldsdottir, H., Mo, M. L., Rolfsson, O., Stobbe, M. D., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2488 · Cited by 1,019
Subgroup-specific structural variation across 1,000 medulloblastoma genomes
Northcott, P. A., Shih, D. J. H., Peacock, J., Garzia, L., Sorana Morrissy, A., Zichner, T., Stütz, A. M., Korshunov, A., Reimand, J., Schumacher, S. E., et al. (2012) · Nature · doi:10.1038/nature11327 · Cited by 899 · cited 2×
“A role for deregulated TGF β signalling in Group 3 has been suggested in our previous genomic/epigenomic studies 11,32 ; however, functional studies that further substantiate these observations are still lacking.”
Self-citationRausch, T., Jones, D. T. W., Zapatka, M., Stütz, A. M., Zichner, T., Weischenfeldt, J., Jäger, N., Remke, M., Shih, D., Northcott, P. A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.013 · Cited by 865 · cited 17×
“%) were determined to be in-frame insertions clustered across just six amino acids within the KBTBD4 Kelch domain (Fig.”
InfluentialSelf-citationNovel mutations target distinct subgroups of medulloblastoma
Robinson, G., Parker, M., Kranenburg, T. A., Lu, C., Chen, X., Ding, L., Phoenix, T. N., Hedlund, E., Wei, L., Zhu, X., et al. (2012) · Nature · doi:10.1038/nature11213 · Cited by 846 · cited 2×
“Re-analysis of NGS data derived from previous studies ( n = 173) 5,9,14 indicated that less than one-third of Group 3 (32”
Self-citationDissecting the genomic complexity underlying medulloblastoma
Jones, D. T. W., Jäger, N., Kool, M., Zichner, T., Hutter, B., Sultan, M., Cho, Y.-J., Pugh, T. J., Hovestadt, V., Stütz, A. M., et al. (2012) · Nature · doi:10.1038/nature11284 · Cited by 839 · cited 1×
“CTDNEP1 (5) KMT2D (7) KBTBD4 (8) SMARCA4 (12) MYC (20) Group 3 coverage: 34.”
Self-citationRecurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
the International Cancer Genome Consortium PedBrain Tumor Project, Jones, D. T. W., Hutter, B., Jäger, N., Korshunov, A., Kool, M., Warnatz, H.-J., Zichner, T., Lambert, S. R., Ryzhova, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2682 · Cited by 825
Self-citationGenome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition
Kool, M., Jones, D. T. W., Jäger, N., Northcott, P. A., Pugh, T. J., Hovestadt, V., Piro, R. M., Esparza, L. A., Markant, S. L., Remke, M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.004 · Cited by 762 · cited 2×
“Building on our previous work 6 , we reliably assigned at least one driver gene to more than 95% of patients with SHH MB, and revealed several insights that extend beyond genetic events that target the canonical SHH signalling pathway (Extended Data Fig.”
Self-citationMedulloblastoma exome sequencing uncovers subtype-specific somatic mutations
Pugh, T. J., Weeraratne, S. D., Archer, T. C., Pomeranz Krummel, D. A., Auclair, D., Bochicchio, J., Carneiro, M. O., Carter, S. L., Cibulskis, K., Erlich, R. L., et al. (2012) · Nature · doi:10.1038/nature11329 · Cited by 750 · cited 2×
“Re-analysis of NGS data derived from previous studies ( n = 173) 5,9,14 indicated that less than one-third of Group 3 (32”
Self-citationKool, M., Koster, J., Bunt, J., Hasselt, N. E., Lakeman, A., van Sluis, P., Troost, D., Meeteren, N. S.-V., Caron, H. N., Cloos, J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003088 · Cited by 722
Self-citationThe Genetic Landscape of the Childhood Cancer Medulloblastoma
Parsons, D. W., Li, M., Zhang, X., Jones, S., Leary, R. J., Lin, J. C.-H., Boca, S. M., Carter, H., Samayoa, J., Bettegowda, C., et al. (2011) · Science · doi:10.1126/science.1198056 · Cited by 717 · cited 1×
“Consistent with our previous studies 23,24 , genetic events targeting histone modifiers, especially those regulating lysine methylation and/ or acetylation, were found across subgroups and contributed to a considerable proportion of cases (Extended Data Fig.”
Self-citationCho, Y.-J., Tsherniak, A., Tamayo, P., Santagata, S., Ligon, A., Greulich, H., Berhoukim, R., Amani, V., Goumnerova, L., Eberhart, C. G., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.5148 · Cited by 717 · cited 1×
“Notable similarities between Group 3 and Group 4 have been discussed, including ambiguous cases that exhibit features characteristic of either subgroup 33–35 .”
Self-citationMuSiC: Identifying mutational significance in cancer genomes
Dees, N. D., Zhang, Q., Kandoth, C., Wendl, M. C., Schierding, W., Koboldt, D. C., Mooney, T. B., Callaway, M. B., Dooling, D., Mardis, E. R., et al. (2012) · Genome Research · doi:10.1101/gr.134635.111 · Cited by 677
Medulloblastomics: the end of the beginning
Northcott, P. A., Jones, D. T. W., Kool, M., Robinson, G. W., Gilbertson, R. J., Cho, Y.-J., Pomeroy, S. L., Korshunov, A., Lichter, P., Taylor, M. D., et al. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3410 · Cited by 663 · cited 2×
“The latter has direct clinical ramifications given that positivity for either of these two features is now routinely used to clinically assign patients to this subgroup, an approach that will currently miss approxi mately 10–15% of bona fide patients with WNT MB. Additional WNT subgroup-associated mutations included s…”
Self-citationEpigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation
Wilson, B. G., Wang, X., Shen, X., McKenna, E. S., Lemieux, M. E., Cho, Y.-J., Koellhoffer, E. C., Pomeroy, S. L., Orkin, S. H., & Roberts, C. W. M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.09.006 · Cited by 654 · cited 1×
“Given the epigenetic antagonism known to exist between SWI/SNF and the PRC2 polycomb repressive complex 26 trials (NCT02601937) and based on our findings here, could represent a rational targeted therapy for treating WNT MB.”
Self-citationEnhancer hijacking activates GFI1 family oncogenes in medulloblastoma
Northcott, P. A., Lee, C., Zichner, T., Stütz, A. M., Erkek, S., Kawauchi, D., Shih, D. J. H., Hovestadt, V., Zapatka, M., Sturm, D., et al. (2014) · Nature · doi:10.1038/nature13379 · Cited by 642 · cited 2×
“In the coding space and as expected, several known and presumed MB driver genes were revealed in our series, including PTCH1 , DDX3X , KMT2D (formerly known as MLL2 ) and others, many of which showed clear subgroup-specificity (Fig.”
Self-citationFast and efficient QTL mapper for thousands of molecular phenotypes
Ongen, H., Buil, A., Brown, A. A., Dermitzakis, E. T., & Delaneau, O. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btv722 · Cited by 598
IntOGen-mutations identifies cancer drivers across tumor types
Gonzalez-Perez, A., Perez-Llamas, C., Deu-Pons, J., Tamborero, D., Schroeder, M. P., Jene-Sanz, A., Santos, A., & Lopez-Bigas, N. (2013) · Nature Methods · doi:10.1038/nmeth.2642 · Cited by 586
iRefIndex: A consolidated protein interaction database with provenance
Razick, S., Magklaras, G., & Donaldson, I. M. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-405 · Cited by 577
Johann, P. D., Erkek, S., Zapatka, M., Kerl, K., Buchhalter, I., Hovestadt, V., Jones, D. T. W., Sturm, D., Hermann, C., Segura Wang, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.001 · Cited by 571
Self-citationComprehensive identification of mutational cancer driver genes across 12 tumor types
Tamborero, D., Gonzalez-Perez, A., Perez-Llamas, C., Deu-Pons, J., Kandoth, C., Reimand, J., Lawrence, M. S., Getz, G., Bader, G. D., Ding, L., et al. (2013) · Scientific Reports · doi:10.1038/srep02650 · Cited by 484
A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers
Lee, R. S., Stewart, C., Carter, S. L., Ambrogio, L., Cibulskis, K., Sougnez, C., Lawrence, M. S., Auclair, D., Mora, J., Golub, T. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64400 · Cited by 428
Self-citationNorthcott, P. A., Nakahara, Y., Wu, X., Feuk, L., Ellison, D. W., Croul, S., Mack, S., Kongkham, P. N., Peacock, J., Dubuc, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.336 · Cited by 412 · cited 1×
“Consistent with our previous studies 23,24 , genetic events targeting histone modifiers, especially those regulating lysine methylation and/ or acetylation, were found across subgroups and contributed to a considerable proportion of cases (Extended Data Fig.”
Self-citationWeischenfeldt, J., Dubash, T., Drainas, A. P., Mardin, B. R., Chen, Y., Stütz, A. M., Waszak, S. M., Bosco, G., Halvorsen, A. R., Raeder, B., et al. (2017) · Nature Genetics · doi:10.1038/ng.3722 · Cited by 404 · cited 4×
“Application of CESAM to MB ( n = 164) confidently identified GFI1B among the most highly significant candidate genes subject to enhancer hijacking, substantiating the robustness of our method (Extended Data Fig.”
InfluentialSelf-citationNotch1 and Notch2 Have Opposite Effects on Embryonal Brain Tumor Growth
Fan, X., Mikolaenko, I., Elhassan, I., Ni, X., Wang, Y., Ball, D., Brat, D. J., Perry, A., & Eberhart, C. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1446 · Cited by 382 · cited 1×
“Aberrant Notch signalling has been repeatedly suggested in the MB literature 30,31 ; however, this is, to our knowledge, the first report documenting Notch pathway mutations in samples from patients with MB.”
Active medulloblastoma enhancers reveal subgroup-specific cellular origins
Lin, C. Y., Erkek, S., Tong, Y., Yin, L., Federation, A. J., Zapatka, M., Haldipur, P., Kawauchi, D., Risch, T., Warnatz, H.-J., et al. (2016) · Nature · doi:10.1038/nature16546 · Cited by 380 · cited 2×
“A role for deregulated TGF β signalling in Group 3 has been suggested in our previous genomic/epigenomic studies 11,32 ; however, functional studies that further substantiate these observations are still lacking.”
Self-citationDivergent clonal selection dominates medulloblastoma at recurrence
Morrissy, A. S., Garzia, L., Shih, D. J. H., Zuyderduyn, S., Huang, X., Skowron, P., Remke, M., Cavalli, F. M. G., Ramaswamy, V., Lindsay, P. E., et al. (2016) · Nature · doi:10.1038/nature16478 · Cited by 334 · cited 3×
“For the final display of mutual exclusivity figures, we excluded genes from the Group 3 module displayed ( k = 4, t = 2) to highlight the relationship of mutually exclusive genes with higher alteration frequency; and we combined two Group 4 modules from two different CoMEt runs ( k = 3, t = 2 and k = 3, t = 3) to crea…”
Self-citationCytogenetic Prognostication Within Medulloblastoma Subgroups
Shih, D. J. H., Northcott, P. A., Remke, M., Korshunov, A., Ramaswamy, V., Kool, M., Luu, B., Yao, Y., Wang, X., Dubuc, A. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9539 · Cited by 313 · cited 1×
“Still, considerable molecular and clinical heterogeneity has been demonstrated 11,40 , suggesting that currently defined MB subgroups are likely to be an oversimplification of true molecular substructure.”
Self-citationA comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing
Alioto, T. S., Buchhalter, I., Derdak, S., Hutter, B., Eldridge, M. D., Hovig, E., Heisler, L. E., Beck, T. A., Simpson, J. T., Tonon, L., et al. (2015) · Nature Communications · doi:10.1038/ncomms10001 · Cited by 306 · cited 1×
“To increase the already high specificity of the workflows 45 , we manually checked all functional variants (non-synonymous, stop-gain, stop-loss and splice-site SNVs and in-frame, frame-shift and splice-site indels), in genes that had at least three hits in the cohort.”
Self-citationHovestadt, V., Remke, M., Kool, M., Pietsch, T., Northcott, P. A., Fischer, R., Cavalli, F. M. G., Ramaswamy, V., Zapatka, M., Reifenberger, G., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1126-5 · Cited by 292 · cited 2×
“For the final display of mutual exclusivity figures, we excluded genes from the Group 3 module displayed ( k = 4, t = 2) to highlight the relationship of mutually exclusive genes with higher alteration frequency; and we combined two Group 4 modules from two different CoMEt runs ( k = 3, t = 2 and k = 3, t = 3) to crea…”
Self-citationStructural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases
Canning, P., Cooper, C. D. O., Krojer, T., Murray, J. W., Pike, A. C. W., Chaikuad, A., Keates, T., Thangaratnarajah, C., Hojzan, V., Marsden, B. D., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.437996 · Cited by 284 · cited 3×
“All mutations observed in our MB series occur in the loop between the second and third strands of the second Kelch ‘blade’, a known substrate recognition hotspot 36 .”
MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in Medulloblastoma
Garzia, L., Andolfo, I., Cusanelli, E., Marino, N., Petrosino, G., De Martino, D., Esposito, V., Galeone, A., Navas, L., Esposito, S., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004998 · Cited by 255
Self-citationCoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer
Leiserson, M. D., Wu, H.-T., Vandin, F., & Raphael, B. J. (2015) · Genome Biology · doi:10.1186/s13059-015-0700-7 · Cited by 210 · cited 1×
“Combinations of Mutually Exclusive Alterations (CoMEt) is a computational tool that is designed to identify mutually exclusive mutations (and other genomic events) in a binary gene by sample matrix 63 .”
Tuncbag, N., Gosline, S. J. C., Kedaigle, A., Soltis, A. R., Gitter, A., & Fraenkel, E. (2016) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004879 · Cited by 171 · cited 3×
“We then used the ‘Forest’ tool from the Omics Integrator suite 58 that solves the Prize Collecting Steiner Forest (PCSF) problem to reduce the size of the network around the genomic alterations (SNVs, indels, CNVs) used as inputs.”
InfluentialSelf-citationDavis, C. A., Haberland, M., Arnold, M., Sutherland, L. B., McDonald, O. G., Richardson, J. A., Childs, G. J., Harris, S., Owens, G. K., & Olson, E. N. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2626-2636.2006 · Cited by 131
Mori, T., Nagase, H., Horii, A., Miyoshi, Y., Nakatsuru, S., Aoki, T., Arakawa, H., Nakamura, Y., Shimano, T., Yanagisawa, A., et al. (1994) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870090304 · Cited by 123 · cited 1×
“…CTNNB1 wild-type MBs harboured pathogenic APC germline variants, explaining the WNT pathway activation seen in these patients and underscoring the need to perform genetic testing for APC carrier status (that is, Turcot syndrome) 25 when WNT MB is suspected despite failure to detect mutant CTNNB1 .”
Parent-specific copy number in paired tumor–normal studies using circular binary segmentation
Olshen, A. B., Bengtsson, H. L., Neuvial, P., Spellman, P. T., Olshen, R. A., & Seshan, V. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr329 · Cited by 122 · cited 1×
“The genome was segmented using the PSCBS package in R 49 while incorporating structural variant breakpoints defined by DELLY.”
Data analysis: Create a cloud commons
Stein, L. D., Knoppers, B. M., Campbell, P. J., Getz, G. A., & Korbel, J. O. (2015) · Nature · doi:10.1038/523149a · Cited by 111 · cited 4×
“SNVs. SNVs were called using the DKFZ samtools-based 42 calling pipeline as described 3,5 using the ICGC PanCancer version.”
InfluentialSelf-citationBiallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors
Decker, B. J., Karyadi, D. M., Davis, B. W., Karlins, E., Tillmans, L. S., Stanford, J. L., Thibodeau, S. N., & Ostrander, E. A. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.03.003 · Cited by 51 · cited 1×
“…previously detected in MB 16 and has been linked with underlying BRCA1 and BRCA2 mutations in breast, aggressive prostate, and pancreatic cancers 16,17 , was unexpectedly observed in most of the patients with Group 3 and Group 4 MB, and a subset of patients with SHH MB. Additional…”
Deep Sequencing Identifies IDH1 R132S Mutation in Adult Medulloblastoma
Snuderl, M., Triscott, J., Northcott, P. A., Shih, H. A., Kong, E., Robinson, H. E., Dunn, S. E., Iafrate, A. J., & Yip, S. S. F. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4864 · Cited by 21 · cited 1×
“We identified six IDH1 R132C mutations (five SHH, one WNT), consistent with a recent case report 29 (Extended Data Fig.”
Self-citation
Cited by
Pan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064
Self-citationOstrom, Q. T., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab200 · Cited by 2,529
Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz150 · Cited by 2,585
Ostrom, Q. T., Gittleman, H., Truitt, G., Boscia, A., Kruchko, C., & Barnholtz-Sloan, J. S. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy131 · Cited by 2,138
Ostrom, Q. T., Patil, N., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa200 · Cited by 1,789
Metadata
- Authors
- Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., Warnatz, H.-J., Sidiropoulos, N., Phillips, A. H., Schumacher, S., Kleinheinz, K., Waszak, S. M., Erkek, S., Jones, D. T. W., Worst, B. C., Kool, M., Zapatka, M., Jäger, N., Chavez, L., Hutter, B., Bieg, M., Paramasivam, N., Heinold, M., Gu, Z., Ishaque, N., Jäger-Schmidt, C., Imbusch, C. D., Jugold, A., Hübschmann, D., Risch, T., Amstislavskiy, V., Gonzalez, F. G. R., Weber, U. D., Wolf, S., Robinson, G. W., Zhou, X., Wu, G., Finkelstein, D., Liu, Y., Cavalli, F. M. G., Luu, B., Ramaswamy, V., Wu, X., Koster, J., Ryzhova, M., Cho, Y.-J., Pomeroy, S. L., Herold-Mende, C., Schuhmann, M., Ebinger, M., Liau, L. M., Mora, J., McLendon, R. E., Jabado, N., Kumabe, T., Chuah, E., Ma, Y., Moore, R. A., Mungall, A. J., Mungall, K. L., Thiessen, N., Tse, K., Wong, T., Jones, S. J. M., Witt, O., Milde, T., Von Deimling, A., Capper, D., Korshunov, A., Yaspo, M.-L., Kriwacki, R., Gajjar, A., Zhang, J., Beroukhim, R., Fraenkel, E., Korbel, J. O., Brors, B., Schlesner, M., Eils, R., Marra, M. A., Pfister, S. M., Taylor, M. D., & Lichter, P.
- Affiliations
- St. Jude Children's Research Hospital (US)
- German Cancer Research Center (DE)
- Hospital for Sick Children (CA)
- University of Copenhagen (DK)
- Massachusetts Institute of Technology (US)
- European Molecular Biology Laboratory (DE)
- Max Planck Institute for Molecular Genetics (DE)
- Broad Institute (US)
- Burdenko Neurosurgery Institute (RU)
- Oregon Health & Science University (US)
- Boston Children's Hospital (US)
- Universitätsklinikum Tübingen (DE)
- University Children's Hospital Tübingen (DE)
- University of California, Los Angeles (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Duke University (US)
- McGill University (CA)
- Kitasato University Hospital (JP)
- BC Cancer Agency (CA)
- University Hospital Heidelberg (DE)
- Corresponding author
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- ORCID
- Northcott, Paul A.
- Buchhalter, Ivo
- Morrissy, A. Sorana
- Hovestadt, Volker
- Weischenfeldt, Joachim
- Zichner, Thomas
- Rudneva, Vasilisa A.
- Warnatz, Hans-Jörg
- Sidiropoulos, Nikos
- Phillips, Aaron H.
- Schumacher, Steven
- Kleinheinz, Kortine
- Waszak, Sebastian M.
- Erkek, Serap
- Jones, David T. W.
- Kool, Marcel
- Zapatka, Marc
- Jäger, Natalie
- Hutter, Barbara
- Bieg, Matthias
- Paramasivam, Nagarajan
- Gu, Zuguang
- Ishaque, Naveed
- Imbusch, Charles D.
- Hübschmann, Daniel
- Amstislavskiy, Vyacheslav
- Robinson, Giles W.
- Zhou, Xin
- Wu, Gang
- Finkelstein, David
- Liu, Yanling
- Cavalli, Florence M. G.
- Ramaswamy, Vijay
- Wu, Xiaochong
- Ryzhova, Marina
- Cho, Yoon-Jae
- Pomeroy, Scott L.
- Schuhmann, Martin
- Ebinger, Martin
- Liau, Linda M.
- Mora, Jaume
- McLendon, Roger E.
- Jabado, Nada
- Kumabe, Toshihiro
- Moore, Richard A.
- Mungall, Andrew J.
- Wong, Tina
- Jones, Steven J. M.
- Witt, Olaf
- Milde, Till
- Capper, David
- Korshunov, Andrey
- Yaspo, Marie-Laure
- Kriwacki, Richard
- Gajjar, Amar
- Zhang, Jinghui
- Beroukhim, Rameen
- Fraenkel, Ernest
- Korbel, Jan O.
- Brors, Benedikt
- Schlesner, Matthias
- Eils, Roland
- Marra, Marco A.
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- Venue
- Nature
- Published
- 2017-07
- Volume
- 547
- Issue
- 7663
- Pages
- 311-317
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5905700
- OpenAlex
- W2737542366
- Cited by
- 1,112
- References
- 66
- Citations by year
- 2026: 63 · 2025: 132 · 2024: 125 · 2023: 154 · 2022: 142 · 2021: 148 · 2020: 120 · 2019: 120 · 2018: 94 · 2017: 12
- FWCI
- 54.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 19 d)
- Locations
- Nature (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Max Planck Digital Library (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
- OPUS (Augsburg University) (submittedVersion, cc-by)
- Funders
- Alexander and Margaret Stewart Trust
- Pediatric Brain Tumor Foundation (R01CA159859)
- Deutsches Krebsforschungszentrum
- Genome Canada (R01CA159859)
- Children's Hospital Foundation
- Ontario Institute for Cancer Research
- American Lebanese Syrian Associated Charities
- Government of Ontario
- Genome British Columbia (R01CA159859)
- Canada Research Chairs
- Brain Tumour Charity (GN-000356)
- Bundesministerium für Bildung und Forschung (01KU1505E, 01KU1201A, 01KU1505A)
- Terry Fox Research Institute (R01CA159859)
- Deutsche Krebshilfe (109252)
- Hospital for Sick Children
- Stichting Kinderen Kankervrij
- BC Cancer Foundation (FDN-143288)
- Brain Tumour Research
- National Institutes of Health
- Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft
- Garron Family Cancer Centre
- National Cancer Institute (R01CA148699, R01CA109467, R01CA159859)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- medulloblastoma, molecular subtypes, driver mutations, somatic mutations, mutational signatures, enhancer hijacking, in-frame insertion, DNA methylation, Group 3 medulloblastoma, Group 4 medulloblastoma, therapeutic target, childhood brain tumours, integrative genomics
- MeSH terms
- Whole Genome Sequencing, Carrier Proteins, DNA Mutational Analysis, Epistasis, Genetic, Humans, Medulloblastoma, Muscle Proteins, Mutation, Oncogenes, Transcription Factors, Cohort Studies, Genome, Human, DNA Methylation, Genomics, Wnt Proteins, Molecular Targeted Therapy, Carcinogenesis, Datasets as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.